Want to see ATXI full AI Analyst Report?
ATXI Stock Chart & Stats
$0.73
-$0.12(-6.36%)
At close: 4:00 PM EST
$0.73
-$0.12(-6.36%)
Day’s Range― - ―
52-Week Range$0.15 - $0.97
Previous CloseN/A
Volume16.16K
Average Volume (3M)2.90K
Market Cap
$1.09M
Enterprise Value-$1.53M
Total Cash (Recent Filing)$2.42M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.05
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding3,294,967
10 Day Avg. Volume2,401
30 Day Avg. Volume2,901
Financial Highlights & Ratios
PEG Ratio-0.22
Price to Book (P/B)1.16
Price to Sales (P/S)1.52
P/FCF Ratio-1.16
Enterprise Value/Market Cap-1.40
Enterprise Value/Revenue-1.09
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.74
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Analyst RecommendationAnalyst maintains a Buy rating on the AJ201 opportunity.
Clinical MilestonesThe company is on track to get to its key milestone, the P2a data for AJ201 in Spinal Bulbar Muscular Atrophy, which is expected in the coming months.
Regulatory PathwayPositive data indicative of potential clinical improvement should pave the way to meet with the FDA to determine next steps.
Bears Say
Capital RequirementsThe company is going to need to raise capital soon, either before or after the data, given the short runway.
Financial PerformanceAvenue reported 2Q24 results with a net loss of ($2.7M) and ended the period with $4.9M in cash on the balance sheet.
Financing NeedsA P2a is planned, but additional financing is needed for which Avenue is exploring its options, including potential partnerships.
Avenue Therapeutics News
ATXI FAQ
What was Avenue Therapeutics Inc’s price range in the past 12 months?
Avenue Therapeutics Inc lowest stock price was $0.15 and its highest was $0.97 in the past 12 months.
What is Avenue Therapeutics Inc’s market cap?
Avenue Therapeutics Inc’s market cap is $1.09M.
When is Avenue Therapeutics Inc’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Avenue Therapeutics Inc’s earnings last quarter?
Currently, no data Available
Is Avenue Therapeutics Inc overvalued?
According to Wall Street analysts Avenue Therapeutics Inc’s price is currently Overvalued.
Does Avenue Therapeutics Inc pay dividends?
Avenue Therapeutics Inc does not currently pay dividends.
What is Avenue Therapeutics Inc’s EPS estimate?
Avenue Therapeutics Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Avenue Therapeutics Inc have?
Avenue Therapeutics Inc has 3,294,967 shares outstanding.
What happened to Avenue Therapeutics Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Avenue Therapeutics Inc?
Currently, no hedge funds are holding shares in ATXI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Avenue Therapeutics Inc
Avenue Therapeutics, Inc. functions as a specialized pharmaceutical enterprise, primarily dedicated to innovating and bringing to market medical therapies tailored for critical and intensive care environments within hospitals. Their leading product candidate is intravenous Tramadol, a synthetic opioid with a dual mechanism of action, currently undergoing Phase III clinical trials for the management of severe pain experienced by patients after surgery. Established in 2015, the company's operations are based in New York, New York.
Technical Analysis
Ownership Overview
―
Insiders
―
Mutual Funds
5.50% Other Institutional Investors
94.50% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---